VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services
VolitionRx has entered a co-marketing agreement with Hologic to promote its Nu.Q® Discover epigenetic profiling service, expanding access to pharmaceutical and academic researchers in a market valued at $200 million annually.
VolitionRx Ltd. has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc., to promote Volition's Nu.Q® Discover service. The program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies. This partnership represents a significant expansion opportunity for Volition's proprietary technology in the growing pharmaco-epigenetics market.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, described the agreement as a significant milestone for the Nu.Q® Discover program. "This will greatly expand customer access to our proprietary Nu.Q® Discover assays, which have an estimated total addressable market of $200 million annually," Kway stated. The company anticipates that working with Hologic will strengthen its position in the pharmaco-epigenetics market and help grow revenues.
Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm for adding Nu.Q® Discover to the company's service offering. "We have extensive experience not only in oncology but also in other disease areas such as cardiovascular, neurodegenerative, immunology and others; disease areas where we believe nucleosome quantification can provide additional valuable biological insights to our biotech, pharma and academic clients," Werding commented. Hologic's broad expertise across multiple disease areas positions the company to effectively market the epigenetic profiling service to diverse research communities.
The agreement establishes Hologic as a co-marketing partner for Nu.Q® Discover with its existing customer base for an initial one-year term. The partnership includes potential for expansion into an exclusive provider arrangement subject to further terms. This strategic alliance leverages Hologic's established relationships in the life sciences sector while providing Volition with expanded market reach for its epigenetic testing technology. For additional information about Volition's technology and services, visit https://www.Volition.com.